Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932483 | 0.81 | CES2 (0.61) | KAT6ACYP11B1CES2CES1ALDH1A1 | |
| SCHEMBL3273583 | 0.81 | TSHR (0.59) | TSHRCES2CES1ALDH1A1KDM4E | |
| SCHEMBL4000363 | 0.80 | CES2 (0.58) | TSHRCES2CES1ALDH1A1KDM4E | |
| SCHEMBL30440405 | 0.77 | MAPT (0.48) | KAT6ACYP11B1TSHRCES2CES1 | |
| SCHEMBL16253911 | 0.77 | MAPT (0.48) | KAT6ACYP11B1TSHRCES2CES1 | |
| Methyl Alcohol SCHEMBL28939417 | 0.77 | CES2 (0.54) | CES2CES1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL401838 | 0.76 | TSHR (0.63) | KAT6ATSHRCES2CES1ALDH1A1 | |
| SCHEMBL9693738 | 0.76 | KAT6A (0.47) | KAT6ACYP11B1TSHRCES2CES1 | |
| SCHEMBL413285 | 0.76 | ALDH1A1 (0.54) | KAT6ACYP11B1TSHRCES2CES1 | |
| SCHEMBL30462062 | 0.76 | TSHR (0.63) | KAT6ATSHRCES2CES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2043656-B1 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | UNIV GREENWICH (GB) | 2014-02-12 | — | — | EP | disclosed |
| US-20130005732-A1 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | UNIVERSITY OF GREENWICH (GB) | 2013-01-03 | — | — | US | disclosed |
| US-8268823-B2 | Medical use of triazine derivatives | UNIVERSITY OF GREENWICH (GB) | 2012-09-18 | — | — | US | disclosed |
| US-20090291954-A1 | Medical Use of Triazine Derivatives | UNIVERSITY OF GREENWICH (GB) | 2009-11-26 | — | — | US | disclosed |
| CN-101516377-A | Novel medical use of triazine derivatives | UNIV GREENWICH (GB) | 2009-08-26 | — | — | CN | disclosed |
| EP-2043656-A2 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | University of Greenwich (GB) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008007149-A2 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | UNIVERSITY OF GREENWICH (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291954-A1 | Medical Use of Triazine Derivatives | KCNH1, KCNJ1, KCNN1 | KAT6A 3145/4885CYP11B1 200/4885TSHR 1045/4885 |
| US-20130005732-A1 | NEW MEDICAL USE OF TRIAZINE DERIVATIVES | KCNJ1, KCNH1, KCNJ11 | KAT6A 3698/4885CYP11B1 289/4885TSHR 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.